News Samsung Biologics agrees $1.81bn takeover of PolyPeptide Samsung Biologics has agreed to buy PolyPeptide, a Swiss CDMO, in what is thought to be South Korea's largest biopharma acquisition to date.
R&D Setting the standard for sustainability in pharma Sustainability has become a crucial pillar in pharmaceutical development, with environmental concerns and resource management demanding immediate attention from organisations of all sizes a
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.